EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access

Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA‐HCM

Caroline J Coats iD, Ahmad Masri iD, Michael E Nassif, Roberto Barriales-Villa iD, Michael Arad iD, Nuno Cardim iD, Lubna Choudhury iD, Brian Claggett iD, Hans-Dirk Düngen, Pablo Garcia-Pavia iD, Albert A Hagège iD, James L Januzzi iD und 25 weitere

Journal of the American Heart Association · 06.08.2024 · 13 (15)

DOI: 10.1161/jaha.124.035993 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of the American Heart Association, erschienen am 06.08.2024. Verfasst von Caroline J Coats und 36 weiteren Autor:innen. Beteiligte Einrichtung: School of Cardiovascular and Metabolic Health University of Glasgow United Kingdom. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic, Stroke Volume, Ventricular Function, Left. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background Aficamten, a novel cardiac myosin inhibitor, reversibly reduces cardiac hypercontractility in obstructive hypertrophic cardiomyopathy. We present a prespecified analysis of the pharmacokinetics, pharmacodynamics, and safety of aficamten in SEQUOIA‐HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM). Methods and Results A total of 282 patients with obstructive hypertrophic cardiomyopathy were randomized 1:1 to daily aficamten (5–20 mg) or placebo between February 1, 2022, and May 15, 2023. Aficamten dosing targeted the lowest effective dose for achieving site‐interpreted Valsalva left ventricular outflow tract gradient

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiomyopathy, HypertrophicStroke VolumeVentricular Function, LeftAdultAgedFemaleHumansMaleMiddle AgedAtrial FibrillationBenzylaminesDose-Response Relationship, DrugDouble-Blind MethodTreatment OutcomeUracil

Stichwörter der Autor:innen

aficamtencardiac myosin inhibitorhypertrophic cardiomyopathy

Substanzen

BenzylaminesMYK-461Uracil

Autor:innen und Institutionen

  • School of Cardiovascular and Metabolic Health University of Glasgow United Kingdom.
  • Oregon Health and Science University Portland OR.
  • University of Missouri Kansas City Healthcare Institute for Innovations in Quality and Saint Luke's Mid America Heart Institute Kansas City MO.
  • Complexo Hospitalario Universitario A Coruña, INIBIC, CIBERCV-ISCIII A Coruña Spain.
  • Leviev Heart Center, Sheba Medical Center Ramat-Gan and Tel Aviv University Ramat-Gan Israel.
  • Hospital CUF Descobertas Lisbon Portugal.

ORCID-Profile: Caroline J Coats, Ahmad Masri, Roberto Barriales-Villa, Michael Arad, Nuno Cardim, Lubna Choudhury, Brian Claggett, Pablo Garcia-Pavia, Albert A Hagège, James L Januzzi, Matthew M Y Lee, Gregory D Lewis, Chang-Sheng Ma, Martin S Maron, Zi Michael Miao, Michelle Michels, Iacopo Olivotto, Artur Oreziak, Anjali T Owens, John A Spertus, Scott D Solomon, Jacob Tfelt-Hansen, Hugh Watkins, Stephen B Heitner, Stuart Kupfer, Fady I Malik

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Coats, C. J., Masri, A., Nassif, M. E., Barriales-Villa, R., Arad, M., Cardim, N., Choudhury, L., Claggett, B., Düngen, H. D., Garcia-Pavia, P., Hagège, A. A., Januzzi, J. L., Lee, M. M. Y., Lewis, G. D., Ma, C. S., Maron, M. S., Miao, Z. M., Michels, M., Olivotto, I., …, & SEQUOIA‐HCM Investigators * (2024). Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA‐HCM. Journal of the American Heart Association, 13(15). https://doi.org/10.1161/jaha.124.035993

Vancouver

Coats CJ, Masri A, Nassif ME, Barriales-Villa R, Arad M, Cardim N, et al. Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA‐HCM. Journal of the American Heart Association. 2024;13(15). doi:10.1161/jaha.124.035993

BibTeX
@article{Coats2024,
  author = {Coats, Caroline J and Masri, Ahmad and Nassif, Michael E and Barriales-Villa, Roberto and Arad, Michael and Cardim, Nuno and Choudhury, Lubna and Claggett, Brian and Düngen, Hans-Dirk and Garcia-Pavia, Pablo and Hagège, Albert A and Januzzi, James L and Lee, Matthew M Y and Lewis, Gregory D and Ma, Chang-Sheng and Maron, Martin S and Miao, Zi Michael and Michels, Michelle and Olivotto, Iacopo and Oreziak, Artur and Owens, Anjali T and Spertus, John A and Solomon, Scott D and Tfelt-Hansen, Jacob and van Sinttruije, Marion and Veselka, Josef and Watkins, Hugh and Jacoby, Daniel L and German, Polina and Heitner, Stephen B and Kupfer, Stuart and Lutz, Justin D and Malik, Fady I and Meng, Lisa and Wohltman, Amy and Abraham, Theodore P and SEQUOIA‐HCM Investigators *, SEQUOIA‐HCM Investigators *},
  title = {Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA‐HCM},
  journal = {Journal of the American Heart Association},
  year = {2024},
  volume = {13},
  number = {15},
  doi = {10.1161/jaha.124.035993}
}
Kostenlos starten →